A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Phase of Trial: Phase III
Latest Information Update: 18 Mar 2019
At a glance
- Drugs Regorafenib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms COAST
- Sponsors Bayer; Bayer HealthCare
- 18 Mar 2019 According to European Clinical Trials Database record the trial has been completed in UK
- 20 Oct 2017 Status changed from completed to discontinued.
- 11 Oct 2016 Status changed from suspended to completed.